<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02402062</url>
  </required_header>
  <id_info>
    <org_study_id>GETNE-1408</org_study_id>
    <secondary_id>2014-004072-30</secondary_id>
    <nct_id>NCT02402062</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours</brief_title>
  <official_title>A Phase II Study to Assess the Activity and Safety of TH-302 in Combination With Sunitinib in Treatment-naïve Patients With Well- and Moderately-differentiated Metastatic Pancreatic Neuroendocrine Tumours (pNET)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol de Tumores Neuroendocrinos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Threshold Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Espanol de Tumores Neuroendocrinos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and the efficacy of the combination of
      the drugs TH-302 and sunitinib in metastatic neuroendocrine tumours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the safety and the efficacy of the combination of
      the drugs TH-302 and sunitinib in Treatment-naïve patients with well- and
      moderately-differentiated metastatic Pancreatic Neuroendocrine Tumours (pNET).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>48 months</time_frame>
    <description>Objective response rate: percentage of patients in whom a complete response (CR) or a partial response (PR) is confirmed according Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria in relation to the total of the analysed population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>48 months</time_frame>
    <description>Time between the start of study treatment to date of the first objective evidence of radiological progression or patient death due to any cause; which comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumour Progression (TTP)</measure>
    <time_frame>48 months</time_frame>
    <description>It is defined as the time between the start of study treatment to date of the first objective evidence of radiological progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DR)</measure>
    <time_frame>48 months</time_frame>
    <description>It is defined as the time between the start from the first documentation of objective response (CR or PR) which is subsequently confirmed until the first objective evidence of radiological progression or death from any cause. DR is calculated only in the subgroup of patients with an objective response (CR + PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OR)</measure>
    <time_frame>48 months</time_frame>
    <description>It is defined as the time between the start of study treatment to date of death from any cause. If it were impossible to obtain confirmation of the death, survival will be censored with the date of the last Visit that it is satisfied that the patient was alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (adverse events)</measure>
    <time_frame>time between the date of signing the informed consent until 28 days after the last dose of study drug</time_frame>
    <description>Safety will be assessed according to the reports of adverse events, the frequency of treatment discontinuations due to adverse events, laboratory evaluations or ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers in serum and tumor tissue</measure>
    <time_frame>48 months</time_frame>
    <description>Assess the predictive/prognostic value of the analysed biomarkers in plasm and tumour.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>TH-302 + Sunitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TH-302 + Sunitinib. Single arm Study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TH-302 + Sunitinib</intervention_name>
    <description>Combination of the two drugs in cycles of 28 days, described as follows:
Sunitinib: 37,5 mg/day Oral everyday of each 28 day cycle.
TH-302: 340 mg/m2 IV on days 8, 15 and 22 of each cycle.</description>
    <arm_group_label>TH-302 + Sunitinib</arm_group_label>
    <other_name>TH-302 + Sutent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 years of age or older.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

          -  Histologically proven diagnosis of pancreatic neuroendocrine tumors (pNET) with Ki67
             assessment of ≤ 20% (well and moderately differentiated)

          -  Evidence of unresectable disease or metastatic disease. Locally advanced disease must
             not be amendable to resection or radiation therapy with curative intent.

          -  Patients may be treated with somatostatin analogues prior or during the trial.
             Concomitant or prior interferon treatment is not permitted.

          -  Documented progression disease by CT scan, magnetic resonance (MR) or Octreoscan in 12
             months prior basal visit.

          -  Measurable disease as per RECIST. Measurable lesions that have been previously
             radiated will not be considered target lesions unless increase in size has been
             observed following completion of radiation therapy.

          -  Patient has to be able to swallow the medication.

          -  Life expectancy greater than 12 weeks.

          -  The definitions of minimum adequacy for organ function required prior to study entry
             are as follows:

               -  Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 2.5 x
                  upper limit of normal (ULN), or AST and ALT ≤ 5 x ULN if liver function
                  abnormalities are due to underlying malignancy

               -  Total serum bilirubin ≤ 1.5 x ULN

               -  Serum albumin ≥ 3.0 g/dL

               -  Absolute neutrophil count (ANC) ≥ 1500/µL

               -  Platelets ≥ 100,000/µL

               -  Hemoglobin ≥ 5,6 mmol/L (9.0 g/dL)

               -  Creatinin clearance &gt; 40 mL/min (Cockcroft and Gault formula)

          -  Adequate cardiac function: 12-lead ECG without pathologic findings (clinically
             significant alterations are allowed) and Echocardiogram / Normal multiple gated
             acquisition scan (MUGA) (LVEF&gt; 50%)

          -  Signed and dated informed consent document indicating that the patient (or legally
             acceptable representative) has been informed of all the pertinent aspects of the trial
             prior to enrollment.

          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory
             tests, and other study procedures.

        Exclusion Criteria:

          -  Previous treatments with chemotherapy, monoclonal antibodies anti-vascular endothelial
             growth factor (VEGF), tyrosine kinase inhibitors, mammalian target of rapamycin (mTOR)
             inhibitors, or interferon are not permitted for the advanced disease.

          -  Prior treatment on another hypoxia-activated prodrug under clinical trial.

          -  Major surgery, radiation therapy, or systemic therapy within 3 weeks of study
             randomization except palliative radiotherapy to non-target metastatic lesions.

          -  Prior high-dose chemotherapy requiring hematopoietic stem cell rescue.

          -  Immunosuppressive drugs such as cyclosporine, tacrolimus, azathioprine, or long-term
             oral glucocorticoids taken concurrently or within last 3 months prior to randomization

          -  Treatment with known inhibitors or inductors of cytochrome P450 3A4 (CYP3A4) or that
             prolong the QT interval in the previous 7 days.

          -  Prior radiation therapy to &gt; 25% of the bone marrow.

          -  Current treatment on another clinical trial.

          -  Uncontrolled brain metastases, spinal cord compression, carcinomatous meningitis, or
             leptomeningeal disease. Patients should have completed surgery or radiation therapy
             for existing brain metastases, should not have documented increase in size over the
             previous 3 months prior to first dose of treatment on study and should be
             asymptomatic.

          -  Diagnosis of any second malignancy within the last 3 years, except for adequately
             treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.

          -  Any of the following within the 12 months prior to starting study treatment:

               -  myocardial infarction,

               -  severe/unstable angina,

               -  coronary/peripheral artery bypass graft,

               -  congestive heart failure class III or IV of the New York Heart Association (NYHA)
                  or patients with clinical history of congestive heart failure class III or IV of
                  the NYHA, unless an echocardiogram or MUGA in the previous 3 months to selection
                  shows a LVEF ? 45 %

               -  significant heart valve disease

               -  cerebrovascular accident including transient ischemic attack

               -  pulmonary embolus.

          -  Ongoing cardiac dysrhythmias of NCI Common Toxicity Criteria for Adverse Effects
             (CTCAE) grade ≥ 2, atrial fibrillation of any grade, or corrected QT interval (QTc)
             interval &gt;450 msec for males or &gt;470 msec for females.

          -  Hypertension that cannot be controlled by medications (&gt;150/100 mmHg despite optimal
             medical therapy)

          -  Chronic obstructive pulmonary disease (COPD) or any other disease concurrent with
             hypoxemia or oxygen saturation &lt; 90% after a march of two minutes.

          -  Current treatment with therapeutic doses of Coumadin (low dose Coumadin up to 2 mg PO
             daily for deep vein thrombosis prophylaxis is allowed).

          -  Known human immunodeficiency virus infection.

          -  Pregnancy or breastfeeding. All female patients with reproductive potential must have
             a negative pregnancy test (serum or urine) prior to inclusion.

          -  Previous allergic reaction to components structurally similar to TH-302 or sunitinib
             or any of the excipients of drugs.

          -  Non-healing wound, fistulae, active peptic ulcer or bone fracture.

          -  Other severe acute or chronic medical or psychiatric condition, or laboratory
             abnormality that would impart, in the judgment of the investigator, excess risk
             associated with study participation or study drug administration, or which, in the
             judgment of the investigator, would make the patient inappropriate for entry into this
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Grande, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Grupo Espanol de Tumores Neuroendocrinos</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Enrique Grande, MD</last_name>
    <phone>0034 93 451 17 24</phone>
    <email>getne@getne.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Catalá d'Oncologia L'Hospitalet</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexandre Teulé, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carlos López, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial de Castellón</name>
      <address>
        <city>Castelló</city>
        <state>Valencia</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Javier Munarriz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jaume Capdevila, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Encarna González, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Enrique Grande, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rocio García-Carbonero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ana Custodio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Isabel Sevilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marta Benavent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2015</study_first_submitted>
  <study_first_submitted_qc>March 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2015</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pNET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Phosphoramide Mustards</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

